There are 119 papers on interstitial lung disease in aging research: 3 trials and 79 observational studies in people, 2 in animals, 1 in cells, 30 reviews. The newest story, Oct 30, 2026: “Blood proteins linked to later lung-scarring disease”.
Telomere length is linked with a lower risk of interstitial lung disease in humans (Outlier-robust Mendelian randomisation using 77 instruments in FinnGen R12) (OR 0.59 per SD longer telomeres, 95% CI 0.49–0.71).
“Longer telomeres reduced ILD risk: outlier-robust IVW odds ratio (OR) 0.59 per standard deviation (SD), 95% CI 0.49-0.71, p = 2.7 x 10^-8”
HumansOutlier-robust Mendelian randomisation using 77 instruments in FinnGen R12
Telomere length is linked with a lower risk of interstitial lung disease in humans (genetically predicted by nine single-nucleotide polymorphisms) (OR 0.29, 95% CI 0.14-0.61, P = 0.001).
Interstitial lung disease is associated with mortality in humans (Rheumatoid arthritis; interstitial lung disease without bronchiectasis) (Adjusted HR 3.16, 95% CI 1.92–5.22).
“The adjusted hazard ratio (95% CI) was 2.37 (1.48–3.82) for bronchiectasis alone and 3.16 (1.92–5.22) for ILD alone.”
HumansRheumatoid arthritis; interstitial lung disease without bronchiectasisMean follow-up of 9.7 yearsn = 766
Interstitial lung disease is associated with mortality in humans (COVID-19) (adjOR = 1.35, 95% CI: 1.28-1.42).
“interstitial lung disease (adjOR = 1.35, CI:1.28-1.42); low or normal body mass index (adjOR:1.03, CI:1.00-1.07); higher comorbidity index (adjOR = 1.01, CI:1.01-1.02)”
Interstitial lung disease is associated with frailty in patients with interstitial lung disease assessed by Fried Frailty Phenotype (35% (95% CI 25%-45%)).
“The pooled prevalence of frailty was 35% (95% CI 25%-45%) by FFP”
Reviewin patients with interstitial lung disease assessed by Fried Frailty Phenotype
Interstitial lung disease is associated with restriction with normal spirometry in humans (aOR 3.65, 95% CI 3.43-3.88).
“Restriction with normal spirometry was more likely in older patients (adjusted odds ratio [aOR] 1.01 per year, 95% CI 1.01-1.01), in non-White patients (aOR 1.33, 95% CI 1.26-1.41), and in patients with a diagnosis (aOR 3.65, 95% CI 3.43-3.88) or radiographic evidence (aOR 3.02, 95% CI 2.79-3.28) of interstitial lung disease (ILD).”
Hydroxychloroquine is linked with a higher risk of interstitial lung disease in humans (compared with methotrexate initiators after propensity score matching) (RR 1.377).
“HCQ initiation was associated with significantly higher 10-year relative risks (RR) for NSTEMI (RR: 1.217), ESRD (RR: 2.624), ILD (RR: 1.377), PAH (RR: 1.625), and all-cause mortality (RR: 1.379)”
Humanscompared with methotrexate initiators after propensity score matching10 yearsn = 56,362
Among 52,743 participants initially free of interstitial lung disease, 277 blood proteins were linked to later diagnoses over an average 14.4 years.Among 52,743 participants initially free of interstitial lung disease, 277 blood proteins were linked to later diagnoses over an average 14.4 years.
Longer telomeres were linked to lower odds of interstitial lung disease, with an odds ratio of 0.59 per standard-deviation increase in length.Longer telomeres were linked to lower odds of interstitial lung disease, with an odds ratio of 0.59 per standard-deviation increase in length.